Clinical trials: Organ Rejection
Organ Transplant Rejection, Psoriasis
Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study
This first-in-human study is designed to assess the safety and pharmacokinetic (PK) profile of sustained-release (SR) depot tacrolimus, which will be administered as a single dose of 0.1 mg/kg by subcutaneous (SC) injection in…
- Trial name
- NCT03626714
- Testing
- Sustained Release Injectable Tacrolimus
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Auritec Pharmaceuticals
Kidney Transplantation, Graft Rejection
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.
- Trial name
- NCT00251004
- Testing
- Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA)
- Where
- United States
- Volunteers
- 833 people
- Sponsor
- Novartis
Transplantation, Organ
A Study of Belimumab in the Prevention of Kidney Transplant Rejection
Kidney transplantation is the best treatment for many patients with kidney failure. Sometimes a transplanted kidney is rejected by the patient's immune system.
- Trial name
- NCT01536379
- Testing
- Belimumab
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Transplant Rejection, Renal Transplantation
Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients
Sirolimus, 1 mg, white, triangular tablets (Rapamune®) was approved on 03 April 2007 in China for prophylaxis of organ rejection in renal transplantation.
- Trial name
- NCT01236378
- Testing
- Sirolimus
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Pfizer